Reig Jofre H1 2026 net income more than doubles to EUR 3.4 million; EBITDA rises 27% to EUR 17.9 million

• Laboratorio Reig Jofre posted H1 2026 net income of EUR 3.4 million, up 126%, as EBITDA climbed 27% to EUR 17.9 million.
• Revenue rose 1% to EUR 168.5 million, despite a temporary Forté Pharma supply-chain disruption in France and Belgium that was resolved in June.
• EBITDA margin improved to 10.7%, while net financial debt stood at EUR 117.7 million, implying a net debt-to-EBITDA ratio of 3.4x.
• Antibiotics sales increased 16% in Q2 versus Q2 2025 as the new Toledo injectable penicillin line began start-up; capacity is expected to lift output 50% over coming years.
• Forté Pharma sales fell 17% in H1, while Specialty Pharmacare sales rose 14% to EUR 67 million and Pharmaceutical Technologies slipped 2% to EUR 69 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorio Reig Jofre SA published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.